TY - JOUR
T1 - Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs
AU - Tartour, Kevin
AU - Nguyen, Xuan Nhi
AU - Appourchaux, Romain
AU - Assil, Sonia
AU - Barateau, Véronique
AU - Bloyet, Louis Marie
AU - Burlaud Gaillard, Julien
AU - Confort, Marie Pierre
AU - Escudero-Perez, Beatriz
AU - Gruffat, Henri
AU - Hong, Saw See
AU - Moroso, Marie
AU - Reynard, Olivier
AU - Reynard, Stéphanie
AU - Decembre, Elodie
AU - Ftaich, Najate
AU - Rossi, Axel
AU - Wu, Nannan
AU - Arnaud, Frédérick
AU - Baize, Sylvain
AU - Dreux, Marlène
AU - Gerlier, Denis
AU - Paranhos-Baccala, Glaucia
AU - Volchkov, Viktor
AU - Roingeard, Philippe
AU - Cimarelli, Andrea
N1 - Publisher Copyright:
© 2017 Tartour et al.
PY - 2017/9
Y1 - 2017/9
N2 - IFITMs are broad antiviral factors that block incoming virions in endosomal vesicles, protecting target cells from infection. In the case of HIV-1, we and others reported the existence of an additional antiviral mechanism through which IFITMs lead to the production of virions of reduced infectivity. However, whether this second mechanism of inhibition is unique to HIV or extends to other viruses is currently unknown. To address this question, we have analyzed the susceptibility of a broad spectrum of viruses to the negative imprinting of the virion particles infectivity by IFITMs. The results we have gathered indicate that this second antiviral property of IFITMs extends well beyond HIV and we were able to identify viruses susceptible to the three IFITMs altogether (HIV-1, SIV, MLV, MPMV, VSV, MeV, EBOV, WNV), as well as viruses that displayed a member-specific susceptibility (EBV, DUGV), or were resistant to all IFITMs (HCV, RVFV, MOPV, AAV). The swapping of genetic elements between resistant and susceptible viruses allowed us to point to specificities in the viral mode of assembly, rather than glycoproteins as dominant factors of susceptibility. However, we also show that, contrarily to X4-, R5-tropic HIV-1 envelopes confer resistance against IFITM3, suggesting that viral receptors add an additional layer of complexity in the IFITMs-HIV interplay. Lastly, we show that the overall antiviral effects ascribed to IFITMs during spreading infections, are the result of a bimodal inhibition in which IFITMs act both by protecting target cells from incoming viruses and in driving the production of virions of reduced infectivity. Overall, our study reports for the first time that the negative imprinting of the virion particles infectivity is a conserved antiviral property of IFITMs and establishes IFITMs as a paradigm of restriction factor capable of interfering with two distinct phases of a virus life cycle.
AB - IFITMs are broad antiviral factors that block incoming virions in endosomal vesicles, protecting target cells from infection. In the case of HIV-1, we and others reported the existence of an additional antiviral mechanism through which IFITMs lead to the production of virions of reduced infectivity. However, whether this second mechanism of inhibition is unique to HIV or extends to other viruses is currently unknown. To address this question, we have analyzed the susceptibility of a broad spectrum of viruses to the negative imprinting of the virion particles infectivity by IFITMs. The results we have gathered indicate that this second antiviral property of IFITMs extends well beyond HIV and we were able to identify viruses susceptible to the three IFITMs altogether (HIV-1, SIV, MLV, MPMV, VSV, MeV, EBOV, WNV), as well as viruses that displayed a member-specific susceptibility (EBV, DUGV), or were resistant to all IFITMs (HCV, RVFV, MOPV, AAV). The swapping of genetic elements between resistant and susceptible viruses allowed us to point to specificities in the viral mode of assembly, rather than glycoproteins as dominant factors of susceptibility. However, we also show that, contrarily to X4-, R5-tropic HIV-1 envelopes confer resistance against IFITM3, suggesting that viral receptors add an additional layer of complexity in the IFITMs-HIV interplay. Lastly, we show that the overall antiviral effects ascribed to IFITMs during spreading infections, are the result of a bimodal inhibition in which IFITMs act both by protecting target cells from incoming viruses and in driving the production of virions of reduced infectivity. Overall, our study reports for the first time that the negative imprinting of the virion particles infectivity is a conserved antiviral property of IFITMs and establishes IFITMs as a paradigm of restriction factor capable of interfering with two distinct phases of a virus life cycle.
UR - http://www.scopus.com/inward/record.url?scp=85030466977&partnerID=8YFLogxK
U2 - 10.1371/journal.ppat.1006610
DO - 10.1371/journal.ppat.1006610
M3 - Article
C2 - 28957419
AN - SCOPUS:85030466977
SN - 1553-7366
VL - 13
JO - PLoS pathogens
JF - PLoS pathogens
IS - 9
M1 - e1006610
ER -